Lynovex Poster Presentations at 33rd North American Cystic Fibrosis Conference (NACFC)
30-Oct-2019
NovaBiotics are the EuropaBio SME of the Month for October
28-Oct-2019
NovaBiotics Prize awarded at Robert Gordon University Ceremony
11-Jul-2019
NovaBiotics to present new data on their novel Cystic Fibrosis drugs at the European CF Society’s Annual Conference
04-Jun-2019
NovaBiotics CEO features in The Top 20 Women in Leading Biotech Roles in Europe
21-May-2019
NovaBiotics presenting new data at European Cystic Fibrosis Conference
13-Mar-2019
Novexatin manuscript published in Antimicrobial Agents & Chemotherapy Journal
12-Mar-2019
NovaBiotics Awarded £1.8m in Small Business Research Innovation-Innovate UK grant funding to Advance its Antifungal Drug Candidate, Novamycin
18-Feb-2019
NovaBiotics Welcomes the UK Governments Announcement on Tackling Antimicrobial Resistance (AMR)
24-Jan-2019
Grant Support for Lynovex
04-Dec-2018
NovaBiotics CEO features in Grant Thornton campaign ‘2018 Faces of a Vibrant Economy’
13-Nov-2018
NovaBiotics at North American Cystic Fibrosis Conference (NACFC), Denver
16-Oct-2018
Positive Top Line Data from the CARE CF 1 Clinical Study of Oral Lynovex in Cystic Fibrosis Exacerbations
10-Jul-2018
NovaBiotics CEO named as one of the top 30 woman leaders in UK healthcare
14-Jun-2018
Cysteamine, an endogenous aminothiol, and cystamine, the disulfide product of oxidation, increase Pseudomonas aeruginosa sensitivity to reactive oxygen and nitrogen species and potentiate therapeutic antibiotics against bacterial infection.
03-Apr-2018
How Lynovex works to boost antibiotics in combatting Pseudomonas aeruginosa infection in cystic fibrosis
19-Mar-2018
NovaBiotics’ Lynovex receives Fast Track Designation for Cystic Fibrosis Exacerbations
12-Mar-2018
NovaBiotics Chief Executive Officer Elected as a Fellow of the Royal Society of Edinburgh
27-Feb-2018
NovaBiotics and BioPharma Dealmakers’ ‘Fighting Infectious Diseases’ Webcast
22-Feb-2018
NovaBiotics Receives Most Innovative EU Biotech SME 2017 Award
23-Nov-2017
Enrolment reaches 50% in Lynovex CARE-CF-1 trial
02-Nov-2017
NovaBiotics at North American Cystic Fibrosis Conference (NACFC), Indianapolis
30-Oct-2017
Reflections from World AMR Congress
19-Oct-2017
EuropaBio announces the finalists for the Most innovative European Biotech SME Awards 2017
18-Oct-2017
NovaBiotics at World Antimicrobial Resistance Congress, Washington
13-Sep-2017
NovaBiotics at ASM/ESCMID Conference
31-Aug-2017
NovaBiotics at the 7th International Meeting on Antimicrobial Peptides
21-Aug-2017
NovaBiotics Chief Executive responds to Public Health England warning on Candida auris fungus
16-Aug-2017
NovaBiotics featured on STV News
04-Aug-2017
New Drug Kills MRSA – including strains with antibiotic resistance
03-Aug-2017
50th patient recruited for CARE- CF-1 Lynovex clinical study
01-Aug-2017
NovaBiotics’ novel antimicrobial Luminaderm highly effective against Multi drug resistant MRSA
16-Jun-2017
NovaBiotics participating in BIO 2017 in San Diego
15-Jun-2017
NovaBiotics at European Cystic Fibrosis Conference in Seville
06-Jun-2017
NovaBiotics at American Society for Microbiology
26-May-2017
30 subjects now randomised in Lynovex CARE-CF-1 trial
10-May-2017
NovaBiotics contribution to ECCMID 2017
13-Apr-2017
NovaBiotics Quality Management System Achieves ISO 9001 certification
11-Apr-2017
NovaBiotics to host live Twitter Lynovex Q&A
24-Mar-2017
NovaBiotics Chief Executive Addresses 'Superbugs & Superdrugs' Conference on Antimicrobial Drug Discovery
21-Mar-2017
NovaBiotics CEO to speak at 19th Superbugs & Superdrugs Conference
17-Mar-2017
NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management
03-Mar-2017
NovaBiotics CEO to speak at 10th Berlin Conference on Life Sciences
21-Feb-2017
NovaBiotics at ECCMID 2017
25-Jan-2017
NovaBiotics CEO featured as one of 15 women leading in European Biotech
18-Jan-2017
NovaBiotics announces first patients dosed in Lynovex clinical study
16-Jan-2017
Commercial Collaboration Deal for (Oral) Lynovex®
05-Aug-2016
NovaBiotics "one to watch" for 2017
14-Jul-2016
NovaBiotics Announces New Data on Cysteamine (Nylexa™) as an Antimicrobial Resistance Breaker in Multi Drug Resistant Bacteria
18-Jun-2016
NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance
07-Jun-2016
NovaBiotics Discusses Innovation for Antimicrobial Resistance at BIO
03-Jun-2016
Lynovex Clinical Trial Data Published
12-May-2016
NovaBiotics wins Investment of the Year
05-Feb-2016
Sad news on NovaBiotics' co-founder and first Chairman
10-Sep-2015
Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus
12-Aug-2015
Positive Lynovex Phase IIa data presented at the 38th European Cystic Fibrosis Symposium
12-Jun-2015
NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management
19-Jan-2015
Dr Deborah O’Neil Named EY UK Health Products & Services Entrepreneur of 2014
07-Oct-2014
NovaBiotics Receives Orphan Drug Status from FDA
16-Sep-2014
Initiation of a Phase IIa Clinical Study for Lynovex® in Cystic Fibrosis
25-Jun-2014
NovaBiotics’ Dr Deborah O’Neil Named as an EY Scotland Entrepreneur of 2014
20-Jun-2014
Collaboration between NovaBiotics and the Cystic Fibrosis Trust
31-Jan-2014
NovaBiotics’ Lynovex® Gains Support From The UK’s Cystic Fibrosis Trust
30-Oct-2013
NovaBiotics Enters into Agreement with Taro
24-Aug-2013
Excellent Results From the Unblinding of the Novexatin® Phase IIa Clinical Trial
08-Jul-2010
NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.
The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including Lynovex (in oral and inhaled form), an orphan drug candidate for cystic fibrosis (CF), Novexatin, a potential step change therapy for onychomycosis and Novamycin, a novel antifungal peptide in development primarily for the treatment of invasive fungal diseases caused by mould & emerging, drug resistant yeasts. Novexatin and Novamycin are among the first in class peptide anti-infectives which the company continues to derive from its proprietary antimicrobial peptide rational drug design platform. Lynovex and Nylexa have been developed as novel antimicrobial adjunct therapies from the company's more recently established aminothiol platform.